Your browser doesn't support javascript.
loading
IRF2 is a master regulator of human keratinocyte stem cell fate.
Mercado, Nicolas; Schutzius, Gabi; Kolter, Christian; Estoppey, David; Bergling, Sebastian; Roma, Guglielmo; Gubser Keller, Caroline; Nigsch, Florian; Salathe, Adrian; Terranova, Remi; Reece-Hoyes, John; Alford, John; Russ, Carsten; Knehr, Judith; Hoepfner, Dominic; Aebi, Alexandra; Ruffner, Heinz; Beck, Tanner C; Jagannathan, Sajjeev; Olson, Calla M; Sheppard, Hadley E; Elsarrag, Selma Z; Bouwmeester, Tewis; Frederiksen, Mathias; Lohmann, Felix; Lin, Charles Y; Kirkland, Susan.
Afiliación
  • Mercado N; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Schutzius G; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Kolter C; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Estoppey D; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Bergling S; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Roma G; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Gubser Keller C; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Nigsch F; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Salathe A; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Terranova R; Preclinical Safety, Translational Medicine, NIBR, Basel, CH-4057, Switzerland.
  • Reece-Hoyes J; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Alford J; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Russ C; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Knehr J; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Hoepfner D; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Aebi A; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Ruffner H; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Beck TC; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Jagannathan S; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Olson CM; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Sheppard HE; Department of Molecular and Human Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Elsarrag SZ; Department of Molecular and Human Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
  • Bouwmeester T; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Frederiksen M; Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056, Basel, Switzerland.
  • Lohmann F; Autoimmunity, Transplantation and Inflammation, NIBR, Basel, CH-4056, Switzerland. Felix.Lohmann@novartis.com.
  • Lin CY; Therapeutic Innovation Center, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. Charles.Y.Lin@bcm.edu.
  • Kirkland S; Department of Molecular and Human Genetics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. Charles.Y.Lin@bcm.edu.
Nat Commun ; 10(1): 4676, 2019 10 14.
Article en En | MEDLINE | ID: mdl-31611556
Resident adult epithelial stem cells maintain tissue homeostasis by balancing self-renewal and differentiation. The stem cell potential of human epidermal keratinocytes is retained in vitro but lost over time suggesting extrinsic and intrinsic regulation. Transcription factor-controlled regulatory circuitries govern cell identity, are sufficient to induce pluripotency and transdifferentiate cells. We investigate whether transcriptional circuitry also governs phenotypic changes within a given cell type by comparing human primary keratinocytes with intrinsically high versus low stem cell potential. Using integrated chromatin and transcriptional profiling, we implicate IRF2 as antagonistic to stemness and show that it binds and regulates active cis-regulatory elements at interferon response and antigen presentation genes. CRISPR-KD of IRF2 in keratinocytes with low stem cell potential increases self-renewal, migration and epidermis formation. These data demonstrate that transcription factor regulatory circuitries, in addition to maintaining cell identity, control plasticity within cell types and offer potential for therapeutic modulation of cell function.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Madre / Queratinocitos / Factor 2 Regulador del Interferón Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Madre / Queratinocitos / Factor 2 Regulador del Interferón Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Suiza